Incyte(us:INCY)
60.55
-0.08%
Updated on 2025-03-31
Open:60.15
Close:60.55
High:60.81
Low:59.10
Prev Close:60.60
Volume:1.69M
Turnover:101.82M
Turnover Ratio:0.87%
Shares:193.52M
MarketCap:11.72B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 625 | 197207726 | 102.94% | 70 | 219 | 279 |
| 2024-03-31 | 609 | 214862374 | 95.69% | 86 | 205 | 246 |
| 2023-12-31 | 594 | 217347278 | 96.90% | 89 | 194 | 253 |
| 2023-09-30 | 554 | 208724891 | 93.14% | 50 | 239 | 203 |
| 2023-06-30 | 576 | 207360187 | 92.85% | 45 | 195 | 275 |
| 2023-03-31 | 598 | 214792823 | 96.29% | 68 | 240 | 221 |
| 2022-12-31 | 597 | 210027792 | 94.29% | 87 | 190 | 248 |
| 2022-09-30 | 577 | 211526046 | 95.09% | 58 | 187 | 252 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Baker Bros. Advisors Lp | 30738524 | 16.05% | -5441141 | -15.04% |
| 2024-06-30 | Blackrock Inc. | 21356274 | 11.15% | -1884196 | -8.11% |
| 2024-06-30 | Vanguard Group Inc | 20375447 | 10.64% | -2340374 | -10.30% |
| 2024-06-30 | Dodge & Cox | 15279343 | 7.98% | -136700 | -0.89% |
| 2024-06-30 | State Street Corp | 10851519 | 5.66% | 951973 | 9.62% |
| 2024-06-30 | Renaissance Technologies Llc | 5218337 | 2.72% | -458100 | -8.07% |
| 2024-06-30 | Geode Capital Management, Llc | 4046638 | 2.11% | -393258 | -8.86% |
| 2024-06-30 | Invesco Ltd. | 3569557 | 1.86% | 751262 | 26.66% |
| 2024-06-30 | Acadian Asset Management Llc | 3560989 | 1.86% | 779243 | 28.01% |
| 2024-06-30 | Lsv Asset Management | 2769892 | 1.45% | 15115 | 0.55% |
About
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Address:1801 Augustine Cut-Off
Website:http://www.incyte.com
Market Movers